We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.
- Authors
Uldrick, Thomas S; Wyvill, Kathleen M; Kumar, Pallavi; O'Mahony, Deirdre; Bernstein, Wendy; Aleman, Karen; Polizzotto, Mark N; Steinberg, Seth M; Pittaluga, Stefania; Marshall, Vickie; Whitby, Denise; Little, Richard F; Yarchoan, Robert
- Abstract
Alternatives to cytotoxic agents are desirable for patients with HIV-associated Kaposi's sarcoma (KS). Vascular endothelial growth factor-A (VEGF-A) contributes to KS pathogenesis. We evaluated the humanized anti-VEGF-A monoclonal antibody, bevacizumab, in patients with HIV-KS.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 13, p1476
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.39.6853